Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPED in relapsed/refractory or advanced NK/T-cell lymphoma
NCT04917250Phase 2Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, pegaspargase, etoposide and dexamethasone in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Beijing Tongren Hospital. Primary endpoint: Overall Response Rate at 24 weeks. Status: unknown.
02
Drugs
gemcitabinepegaspargaseetoposidedexamethasone
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04917250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917250.